Ab&B Bio-Tech (HKG:2627) has launched its initial public offering in Hong Kong, aiming to raise as much as HK$518 million, according to a Thursday prospectus filing.
The China-based vaccine company is offering up to 33.44 million H-shares at between HK$12.90 and HK$15.50 each.
The offer comprises 3.34 million shares for Hong Kong investors and 30.10 million shares for international buyers.
The issuer expects to determine its offer price on or before Aug. 6 and disclose the allocations on Aug. 7. Trading is scheduled to begin on the Hong Kong bourse on Aug. 8.
Proceeds from the IPO will be used to develop and register core products, including influenza and rabies vaccines, advance clinical trials, upgrade production facilities, and support sales, R&D, and general working capital needs.
The joint sponsors for the deal are CITIC Securities and CMB International Capital. The joint bookrunners include CLSA, CMB International Capital, Livermore Holdings, Funde Securities, Aristo Securities, BOCI Asia, and ICBC International Securities.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。